Can Oncotype DX recurrence score (RS) be used in luminal A and luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective study in the Spanish population.
Laura García-Estevez
No relevant relationships to disclose
Ana C Contreras
No relevant relationships to disclose
Isabel Calvo
No relevant relationships to disclose
Maria Fernandez Abad
No relevant relationships to disclose
Juan J de la Cruz
No relevant relationships to disclose
Sofia Perea
No relevant relationships to disclose
Ana Suárez
No relevant relationships to disclose
Fernando López-Ríos
No relevant relationships to disclose
Manuel Hidalgo
No relevant relationships to disclose